Generic placeholder image

Mini-Reviews in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1389-5575
ISSN (Online): 1875-5607

NK-1 Receptor Antagonists: A New Generation of Anticancer Drugs

Author(s): M. Munoz and R. Covenas

Volume 12, Issue 7, 2012

Page: [593 - 599] Pages: 7

DOI: 10.2174/138955712800626692

Price: $65

Open Access Journals Promotions 2
Abstract

After binding to the neurokinin-1 (NK-1) receptor, substance P (SP) induces tumor cell proliferation, angiogenesis, and the migration of tumor cells for invasion and metastasis. After binding to NK-1 receptors, NK-1 receptor antagonists inhibit tumor cell proliferation, angiogenesis and the migration of tumor cells. These antagonists are broad-spectrum antitumor drugs. In addition, in the host they display beneficial effects: anxiolytic, antiemetic, neuroprotector, nephroprotector, hepatoprotector, antiinflammatory and analgesic. In combination therapy with classic cytostatics, NK-1 receptor antagonists have synergic effects and minimize the side-effects of these classic drugs. Thus, NK-1 receptor antagonists could offer a new and promising generation of anticancer drugs.

Keywords: Substance P, neoangiogenesis, metastasis, tumor cells, apoptosis, preprotachykinin A, in situ, malignant melanomas, gastric motility, SP-immunoreactivity, NK-1 receptors

Next »

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy